Horner has more than 40 years of industry experience gained with biotech and big pharma companies. He was most recently ceo of Prestwick Pharmaceuticals, a private CNS company that was sold to Biovail Corporation and Ovation Pharmaceuticals in 2008.
Prior to joining Prestwick, Horner was ceo of Vicuron, a publicly listed anti-infectives company that was sold to Pfizer for US$1.9bn in 2005. He also worked for Ligand Pharmaceuticals following a career at Abbott Laboratories where rose to president of the company’s business in Canada.
‘I have been attracted to this opportunity by the company’s rich pipeline of clinical and pre-clinical drug candidates focused on dermatological indications, its deep understanding of the science behind a number of serious skin disorders, as well as its technology platform with broad utility. I am sure that from this strong base we will be able to generate significant value for Creabilis shareholders,’ said Horner.
Dermatology specialist appoints chairman
George Horner joins Creabilis of Luxembourg
You may also like
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA